Mirum Pharmaceuticals (NASDAQ:MIRM) Stock Gets Price Target Increase from Citigroup

Posted by George Bondi on Oct 12th, 2026

Mirum Pharmaceuticals (NASDAQ:MIRM – Get Free Report) had its price target hoisted by analysts at Citigroup from $160.00 to $184.00 in a research report issued on Monday, Benzinga reports. The firm currently has a “buy” rating on the stock. Citigroup’s price objective indicates a potential upside of 113.80% from the company’s current price.

Several other research analysts also recently commented on MIRM. CLSA set a $146.00 price objective on Mirum Pharmaceuticals in a research note on Monday, June 15th. UBS Group set a $137.00 price objective on Mirum Pharmaceuticals in a report on Thursday, August 27th. Weiss Ratings raised shares of Mirum Pharmaceuticals from a “sell (d-)” rating to a “sell (d)” rating in a research note on Thursday, August 6th. TD Cowen reaffirmed a “buy” rating on shares of Mirum Pharmaceuticals in a research note on Monday. Finally, Robert W. Baird upped their target price on shares of Mirum Pharmaceuticals from $123.00 to $130.00 and gave the stock an “outperform” rating in a report on Tuesday, September 29th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $145.62.

View Our Latest Stock Report on Mirum Pharmaceuticals

Mirum Pharmaceuticals Stock Performance

Shares of MIRM stock traded up $0.05 on Monday, hitting $86.06. The company had a trading volume of 1,211,627 shares, compared to its average volume of 856,101. The firm has a market cap of $5.59 billion, a P/E ratio of -5.91 and a beta of 0.61. Mirum Pharmaceuticals has a twelve month low of $63.23 and a twelve month high of $130.00. The company has a 50-day moving average price of $95.08 and a 200-day moving average price of $100.97. The company has a quick ratio of 2.74, a current ratio of 2.86 and a debt-to-equity ratio of 1.28.

Mirum Pharmaceuticals (NASDAQ:MIRM – Get Free Report) last issued its quarterly earnings data on Wednesday, August 5th. The company reported ($1.06) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.32). Mirum Pharmaceuticals had a negative return on equity of 36.28% and a negative net margin of 139.18%. The firm had revenue of $176.24 million during the quarter, compared to analyst estimates of $166.33 million. During the same quarter last year, the company posted ($0.12) EPS. The company’s revenue was up 37.9% on a year-over-year basis. As a group, equities research analysts predict that Mirum Pharmaceuticals will post -1.31 earnings per share for the current fiscal year.

Insider Activity

In related news, SVP Jolanda Howe sold 40,000 shares of Mirum Pharmaceuticals stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $100.00, for a total transaction of $4,000,000.00. Following the completion of the transaction, the senior vice president directly owned 1,274 shares of the company’s stock, valued at approximately $127,400. The trade was a 96.91% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CFO Eric Bjerkholt sold 6,001 shares of the business’s stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $99.90, for a total value of $599,499.90. Following the completion of the transaction, the chief financial officer directly owned 36,355 shares of the company’s stock, valued at approximately $3,631,864.50. This trade represents a 14.17% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 98,499 shares of company stock valued at $9,797,834 in the last ninety days. 8.32% of the stock is currently owned by company insiders.

Institutional Trading of Mirum Pharmaceuticals

Institutional investors have recently made changes to their positions in the stock. Juncture Wealth Strategies LLC lifted its holdings in shares of Mirum Pharmaceuticals by 10.7% during the 3rd quarter. Juncture Wealth Strategies LLC now owns 5,330 shares of the company’s stock worth $456,000 after acquiring an additional 515 shares during the period. Engineers Gate Manager LP increased its stake in shares of Mirum Pharmaceuticals by 218.2% in the second quarter. Engineers Gate Manager LP now owns 8,143 shares of the company’s stock valued at $953,000 after buying an additional 5,584 shares in the last quarter. Insight Wealth Partners LLC bought a new position in shares of Mirum Pharmaceuticals in the second quarter worth about $395,000. Integrated Wealth Concepts LLC acquired a new position in Mirum Pharmaceuticals during the 2nd quarter worth $27,000. Finally, Arizona State Retirement System lifted its stake in shares of Mirum Pharmaceuticals by 12.6% during the second quarter. Arizona State Retirement System now owns 11,655 shares of the company’s stock valued at $1,364,000 after acquiring an additional 1,306 shares during the period.

Key Mirum Pharmaceuticals News

Here are the key news stories impacting Mirum Pharmaceuticals this week:

Positive Sentiment: Mirum said LIVMARLI met the primary endpoint in the Phase 3 EXPAND study evaluating treatment for cholestatic pruritus associated with ultra-rare cholestatic liver diseases. The result supports the company’s efforts to expand LIVMARLI beyond its existing commercial uses. Mirum Pharmaceuticals Meets Primary Endpoint In Phase 3 LIVMARLI Study
Positive Sentiment: The company reported positive topline Phase 3 results and plans to submit an application to the U.S. Food and Drug Administration in 2027. A successful filing and potential approval could broaden LIVMARLI’s addressable market and provide a future revenue catalyst. Mirum Pharmaceuticals Reports Positive Phase 3 LIVMARLI Results; Plans FDA Filing In 2027
Positive Sentiment: HC Wainwright raised its price target for MIRM to $200 from $195 while maintaining a Buy rating, signaling increased confidence in the company’s valuation following the clinical update.
Neutral Sentiment: Mirum hosted an investor discussion covering the EXPAND study results, while earlier reports had highlighted the planned release of the data. These events provided additional visibility but did not represent separate clinical catalysts. Mirum Investor Call Announcement
Neutral Sentiment: The planned FDA submission is not expected until 2027, leaving regulatory review, approval and commercial execution as important future uncertainties. Recent earnings also showed a loss despite revenue growth, underscoring Mirum’s continuing profitability risk.

About Mirum Pharmaceuticals

(Get Free Report)

Mirum Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing medicines for rare diseases of the liver and gastrointestinal system. The company’s work centers on conditions involving impaired bile acid transport and cholestasis, which can cause serious liver damage and debilitating symptoms such as itching.

Mirum’s primary commercial product is Livmarli (maralixibat), an oral ileal bile acid transporter inhibitor. In the United States, Livmarli is approved to treat cholestatic pruritus associated with Alagille syndrome and progressive familial intrahepatic cholestasis in eligible pediatric patients.